Citadel Advisors
TBIO

Citadel Advisors’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

Citadel Advisors’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,083
Closed -$15K – 15650
2023
Q4 		$15K Buy
2,083
+1,755
+535% +$19.5K ﹤0.01% 12857
2023
Q3 		$6.13K Buy
328
+321
+4,586% +$7.81K ﹤0.01% 13340
2023
Q2 		$201 Buy
7
+6
+600% +$239 ﹤0.01% 14190
2023
Q1 		$62 Buy
+1
New +$35 ﹤0.01% 14604
2022
Q3 		– Sell
-1,728
Closed -$57K – 13839
2022
Q2 		$57K Buy
+1,728
New +$119K ﹤0.01% 11852
2021
Q3 		– Sell
-3,453
Closed -$1.37M – 14857
2021
Q2 		$1.37M Buy
+3,453
New +$1.22M ﹤0.01% 7540

Other funds holding TBIO

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

Citadel Advisors's TBIO Position: Q1 2024 in Review

Citadel Advisors sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q1 2024, closing a stake of 2,083 shares — an estimated $15K sold.

Citadel Advisors first reported a position in TBIO in Q2 2021 and held it in 6 quarters. The position peaked at $1.37M in Q2 2021. 20 funds tracked by Wall St. Rank hold TBIO as of Q1 2024.

  • Citadel Advisors reported no remaining Telesis Bio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 2,083 Telesis Bio, Inc. Common Stock shares in Q1 2024, an estimated $15K.
  • Citadel Advisors first reported a position in Telesis Bio, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
  • Citadel Advisors's Telesis Bio, Inc. Common Stock position peaked at $1.37M in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.